Clinical Trials
10 trialsNCT03725761 2026-06-04
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04527991 2026-06-02
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05089734 2026-05-07
EVOKE-01
Gilead Sciences
Phase 3 Active not recruiting
NCT03964727 2026-04-28
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT05581589 2026-04-27
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Phase 2 Terminated
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed